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The significant rise in NPS use, and particularly the use and misuse of 3,4-
methylenedioxymethamphetamine (MDMA), has resulted in the need for a rapid, 
sensitive and field deployable method to facilitate its detection and subsequent 
quantification. Standards of MDMA and 4-methoxyamphetamine (PMA), a common 
adulterant encountered in tablets of MDMA, were prepared and characterised by 1H 
and 13C NMR, IR and mass spectrometry. 25 seized tablets (provided by Greater 
Manchester Police) were then analysed qualitatively by 1H NMR and GC-MS, with 
acquisition times of 5 and 8 minutes respectively. All seized samples were found to 
contain MDMA only. Subsequent quantification, therefore, focused solely on 
quantifying the amount of MDMA present by primarily using 1H NMR; GC-MS was 
employed as a complimentary technique in this regard. Quantification by 1H NMR 
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1.1 Drugs use (and abuse) 
 
Drug abuse is the continued use of illegal drugs, or the misuse of prescription drugs 
that can lead to health issues and other negative consequences, and a serious public 
health problem that affects almost every community in some way. Each year drug 
abuse causes millions of serious illnesses or injuries and plays a role in many major 
social problems, such as driving under the influence, violence and stress. Drug abuse 
is thought to be an extremely complex disease and quitting usually requires time and 
upmost dedication,1 due to the drugs changing the brain in ways that make the 
thought of having to go without drugs extremely stressful. Abused illicit drugs include 
cocaine, heroin and methamphetamine. They can alter a person’s thinking and 
judgment, leading to health risks. Prescription drugs may also be abused and some 
of the most commonly abused medications are painkillers, specifically opioids. This is 
due to their side effect of inducing a euphoric high2 and are usually only prescribed 
for more severe pains. Amphetamines are also commonly abused and are stimulants 
prescribed to help people with attention deficit hyperactivity disorder (ADHD),3 a mental 
disorder causing the individual several social problems, such as difficulty paying 
attention, abrupt behaviour and hyperactivity. They are drugs which stimulate the 
cardiovascular and central nervous systems4 and are recreationally used as they can 
cause a feeling of euphoria. This group of drugs may also be taken to increase 
wakefulness, improve focus, and enhance sociability.5 
Stress is a well-known risk factor in the development of drug addiction,6 and 
individuals exposed to stress are more likely to abuse alcohol and other drugs. 
Usually, the initial use of drugs is in the aim of finding relief and is the main cause of 
relapse.7 However, there are several stages of drug use that may lead to addiction, 
and young people seem to move more quickly through the stages than do adults.8 
Drugs may be used for the first time as an experiment, done for recreational use, due 
to peer pressure, or simply because the user likes the way it makes them feel. Use 
usually depends on many factors such as how easy it is to get the drugs, location and 
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current trends. Recreational use is when users continue to use drugs to have fun and 
it becomes part of the individual’s social life and use is seen as a ‘normal’ activity. At 
this point the user may still feel they have control over how regularly they use drugs. 
Regular, problematic or risky drug use is when the user begins losing motivation and 
worries about losing their drug source. They begin to believe that drug use is more 
important than all other interests, including studies, work and relationships and use 
of other, ‘harder’ drugs may increase.8 Finally, dependency hits when the user has 
used drugs heavily or for a long period of time. This addiction means the individual is 
now unable to face daily life without their drugs and may be no longer able to control 
their use. As well as causing detrimental health effects, this may also cause 
emotional, psychological and social problems. 
 
1.1.1   Drugs use (and abuse) in Manchester 
 
Drugs are used by many different people and in many situations, and users tend to 
first be introduced to them in their youth. As a result, adolescents are more likely to 
take drugs than older people, with men twice as likely to take drugs than women.9 
Surveys from 2018 showed around 20% of young adults aged 16 to 24 in the UK had 
taken a drug in the last year,10 which equates to around 1.2 million people, and 
around half of them had taken a drug in the past month. Also, the use of Class A drugs 
among younger adults has only been increasing since 2011/12 and is mainly driven 
by the increase in cocaine and ecstasy popularity and availability.  
Young people (16–24 year olds) may begin taking drugs for various reasons, and 
trends in Class A drug use among young adults has shown a great increase in the last 
few years (Figure 1).10 They may do it to try to ‘fit in’ with a group of friends, perhaps 
they have been offered drugs and feel pressured into taking them, or they know other 
people who use them or simply because they want to try something new and 
experience what it is like. However, it could also be used as a coping mechanism when 
affronted by difficult experiences or to deal with any problems they may be facing. In 
whatever circumstance drugs are used, they can still negatively impact the user 
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physically and/or mentally when used excessively or for a long period of time. This is 
when the chance of addiction is high and addiction can often be linked with additional 
mental health problems. This could affect the user’s judgement and they may be 




Figure 1 Recent trends in Class A drug use by young adults10 
 
Rave and dance cultures were identified as an important part within the youth 
communities9 and it was found that an increased level of drug use was associated 
with a higher frequency of visits to highly social settings such as pubs, clubs and 
festivals, such as the Parklife music festival in Manchester, UK. Here, drug tests are 
taking place on-site in order to find the nature of the drug and the amount in each 
sample.11 Despite health warnings, people still take drugs, such as hallucinogenic and 
mood-enhancing drugs, in these settings to enhance their personal experience. They 
can be taken by the users own choice or due to peer pressure from friends or simply 
to look as though they are part of the society. Users who have visited clubs or 
festivals, consumed alcohol, or used another drug, were more likely to have used NPS 




It is known that illicit drug use is now a common feature of homelessness, and 
especially plays a role in the lives of young homeless people13 and those exposed to 
stress and people who had first been exposed to drugs in their youth. Substance 
abuse is thought to be the cause of several mental and physical disorders are seen 
among the homeless. This leads on to mental illness being the reason they experience 
isolation when becoming homeless, feel humiliated and may believe their 
circumstances may never improve, and is ultimately one of the reasons the young 
homeless people death rate in the UK has risen,14 with Manchester being reported as 
one of the major urban areas with the highest estimated numbers of deaths of 
homeless people. Suicide attempts were also significantly associated with 
homelessness, around 50% compared with around 20% of people who had not slept 
in the streets.13 Undoubtedly, it was seen that areas in England with the higher 
deprivation and poverty had significantly more deaths of homeless people than the 
lesser disadvantaged areas. 
Drug and substance misuse and addiction by a majority of the homeless community 
are usually methods for them of coping with stress caused by harassment,15 high 
levels of illness, physical hardships and mental problems. This stress may be 
temporarily alleviated through drug use and users tend to get “geared up” on drugs 
such as heroin to cope and “ease the pain” from poor health and end up becoming 
addicted.13 Users are unlikely to have the ability to abstain from taking these drugs 
as they believe for this self-medication to be a useful strategy. However, a large 
majority of reported illnesses attained by the homeless, whether mental and/or 
physical, could be traced back to the individual’s drug use.16 Cannabis generally 
seems to be the most popular choice, but stronger drugs, particularly the opiates, 
seemed to deal with the worst aspects of homelessness more effectively and 
evidently there were risks of transitioning to ‘harder drugs’.13 
 




There are many medicinal substances which, if misused, have undesirable side-
effects, including addiction,17 mental illness and overdose. Controlled drugs (or 
substances) are drugs, which are considered dangerous or addictive in the UK and are 
therefore regulated by the law. The Misuse of Drugs Act (1971) [MDA] is the 
legislative apparatus, which is used to classify drugs and control their use and 
distribution. The act states all illegal drugs known in the UK and divides them into one 
of three classes18 (A, B and C). Class A drugs (e.g. heroin, cocaine, ecstasy) represent 
those deemed most abusive and would pose the greatest danger (e.g. addiction), and 
so carry the harshest punishments whereas Class C (e.g. anabolic steroids, GHB and 
some tranquilisers) represents those thought to have the least capacity for harm, and 
so the Act demands more lenient punishment. Class B drugs (e.g. cannabis, ketamine, 
mephedrone) are not deemed as dangerous as those in Class A, however are more 
harmful than Class C so carry a heftier punishment. Certain Class B drugs can be 
reclassified to Class A if they have been prepared for administration by injection. 
The maximum penalty for the possession of drugs are seven years imprisonment fine 
for Class A, five years for Class B and two years for Class C. The maximum penalty for 
the supply and possessions with intent to supply drugs, however, is much greater, 
with the penalties being life imprisonment for Class A and fourteen years 
imprisonment for Classes B and C.18 All the imprisonment penalties carry a possible 
unlimited fine, depending on the crime. The Act was put in place to prevent the 
supply of controlled drugs and achieved this by posing a ban on the production, 
supply and possession of controlled drugs. Drug schedules are associated with the 
medicinal and therapeutic uses of a drug.19 They range from schedule 1, which are 
drugs that are not used medicinally, to schedule 5, which are drugs which can be sold 
over the counter. Some Class A drugs, such has MDMA, have no therapeutic use and 
therefore cannot be lawfully possessed or prescribed and are controlled under the 
Misuse of Drugs Act within Schedule 1. However, although the Class A drug heroin 
has the potential for significant harm, it is used medically for pain relief and is a 
Schedule 2 substance, whilst mephedrone is a Class B (potentially less harmful) but 
has no medicinal value/usage and therefore is a Schedule 1 substance.  Drug class is 
what the courts utilise in sentencing. In the 1990s the emphasis in UK government 
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policy was on reducing demand, whilst the focus in the 2000s was on harm 
reduction.20 The MDA, therefore, must keep abreast of these developments in order 
to maintain its relevancy into which drugs are being misused and to which extent this 
is occurring. 
 
1.3 NPS  
 
New psychoactive substances (NPS), also known as ‘designer drugs’,21 are a range of 
drugs that have been designed to imitate various prohibited drugs such as ecstasy, 
cocaine and cannabis. They are defined as ‘Narcotic or psychotropic drugs that are 
not scheduled under the United Nations 1961 or 1971 Conventions, but which may 
pose a threat to public health comparable to scheduled substances’.22 They are 
produced by altering chemical structures of the active functional groups found in 
traditional illicit drugs, hence allowing manufacturers to create new analogues. These 
drugs can be identified from the originals due to there being little to no history of 
them being used in medicinal circumstances. However, in the production and use of 
NPS there can be several side effects due to contaminants, this could have 
detrimental effects as the chemicals produced are not being tested thoroughly. For 
example, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Figure 2, left) was 
found in prodine23 (Figure 2, middle), which is an analogue of pethidine (meperidine, 
Figure 2, right) and has a similar effect to that of morphine. This then led to a number 
of injecting drug users to become affected by Parkinson's disease.24  
 
Figure 2 Chemical structures of MPTP, Prodine and Pethidine 
MPTP Prodine Pethidine 
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The greatest rise in psychoactive substance use was in 1979 when the production 
designer drugs (synthetic opiates) started to emerge and use of illicit substances 
reached new heights,25 and became apparent after a number of deaths due to drug 
poisoning and overdose. When street samples sold as heroin were seized by law 
enforcement officials and were tested, the results showed the substances were not 
of any known drug. It was identified as alpha-methylfentanyl, an analogue of 
fentanyl, an opioid that is like morphine but 50 to 100 times more potent.26 Although 
the substances produced very similar effects to fentanyls, benzylpiperazines and 
cathinones (etc.), it was classified as a new substance and was not lawfully 
controlled.25 This led to manufacturers of these drugs attempting to develop new 
chemical structures of these analogues to replace those that were banned, which 
resulted in the chemical structure constantly changing.27 This was being achieved in 
illegal, unlicensed laboratories that were being used to synthesise the drugs that 
imitate the pharmacological effects of controlled substances to escape legislation 
controls28 and to try to stay ahead of the law.  
Due to new structures being constantly produced and released onto the drugs 
market, both principal drugs and their metabolites do not have reference standards 
in the chemical databases of drug analytic detection systems (such as GC-MS and 
NMR). This has led to increasing challenges for forensic and clinical laboratories in 
both the identification and quantification of psychoactive substances. Additional 
difficulties in analysis of these substances arise due to the complexity of some 
analytes, particularly when mixtures, due to high levels of adulteration put in place 
to attempt to disguise the drug. These developments led to the Psychoactive 
Substances Act (2016) [PSA] coming into force, which made it an offence to produce, 
supply or offer to supply any substances that produce a psychoactive effect within an 
individual. Penalties relating to this offence can subject an individual to a maximum 
sentence of 7 years’ imprisonment and/ or a fine if they are caught offending.29 
However, simply being in possession of a psychoactive substance is not an offence 
unless it is within a custodial institution, such as prisons.  
The Act came into play with the aim of working against the producers and sellers of 
NPS, aiming to reduce the numbers of dealers, shops and websites that supply these 
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products. It was hoped that subjecting producers and dealers to a sentence would 
emphasise the dangers of NPS and the number of people consuming them would 
decrease, therefore decreasing the death rate due to drug intoxication and poisoning. 
However, it was argued that the ban would only increase the death rates related to 
NPS, since the supply of these substances may be driven underground.30 It was 
envisaged that this would decrease the research and knowledge relating to dosage, 
and due to the movement of the drugs becoming hidden, it would become more 
difficult to detect them. 
 
1.3.1 The Chemistry of MDMA 
 
3,4-methylenedioxymethamphetamine (MDMA, Molly or Ecstasy), shown in Figure 
3, is a widely used Class A synthetic drug which acts as a stimulant and hallucinogen.31 
MDMA is prevalent on the recreational market, as it is commonly used at festivals, 
concerts and clubs. Due to its popularity, the number of both illegal and legal drug 
related deaths in England and Wales was 4,359 in 2018, the highest annual increase 
(16%) since the records began in 1993.32 Ecstasy is often used to refer to MDMA in 
the tablet/capsule form, which is the most common way people use the drug.33 On 
average, the effects of the drug when taken in this form can be felt around 45 minutes 
later and last an average of 3 hours34 even though effects can be experienced up to 
days later. It has been determined that many ecstasy tablets can contain a variety of 
concentrations of MDMA along with several other drugs or drug combinations that 
can be harmful.35 
 
 




MDMA is predominantly used among young adults and adolescents. Social 
interactions often see the drug being abused at night clubs36 and at festivals. This is 
due to the intoxicating effect of the drug. Other effects include increased 
extroversion, an enhanced sense of well-being37 and increased empathy towards 
others.38 However, the use of MDMA also has several health effects. Fatal overdoses 
can be potentially life threatening with symptoms including hypertension (high blood 
pressure), increased anxiety resulting in panic attacks and, in severe cases, 
unconsciousness and seizures.39 
MDMA is readily absorbed from the digestive tract. Onset of action is within 30 
minutes and the user’s peak experience of the drug occurs after one to three hours.40 
With an elimination half-life of around 7 hours, the user may overdose and saturate 
themselves unknowingly. The drug causes the body to retain water41 and due to its 
stimulant effects, it is associated with vigorous physical activity. The combination of 
use and effect causes dehydration39 leading some people to drink large amounts of 
liquids. This can cause a sodium/electrolyte imbalance in the body that can lead to 
kidney failure42 and swelling in the brain that could be fatal. Therefore, the aim to 
design a rapid detection and concentration determination system would be highly 
desirable. Regular use of MDMA has been known to cause sleep disturbances, 
depression, lack of appetite and heart disease.43 However, more research is needed 
to understand the specific effects of regular MDMA use as no long-term assessments 
have yet been carried out. 
Several pills known to be sold as ecstasy were tested and found to contain PMA (4-
methoxyamphetamine, Figure 4), a compound with similar effects to ecstasy but with 
a higher toxicity and with higher lethality at lower doses.44 This compound could also 
be used to adulterate tablets of MDMA, providing the desired effects with a smaller 
amount of compound. This was highlighted in a study from 2008, where a young male 
was admitted to a local hospital in Norway in a coma, and suffering from seizures, 
after taking the drug at a party.45 He was diagnosed with PMA poisoning after 
apparently overdosing on the drug, having taken it in combination with MDMA. 
Adulteration of drugs in this way may be linked to drug-related deaths (DRDs) in the 
UK being at their highest levels since records began in 1993. There has been a 
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significant rise in the number of drug related deaths year on year, with the male drug 
poisoning rate, in England and Wales, increasing 18% from 2017 to 2018 whereas the 
female drug poisoning in 2018 was not statistically significant compared to 2017.46 
Most recorded cases of drug poisonings are because of drug misuse, and intoxications 




Figure 4 Chemical structure of PMA 
 
Figure 5 shows the rate of male deaths related to drug poisoning has doubled since 
1993 whereas the rate at which female deaths related to drug poisoning has 
increased at a much steadier rate. In studies, male drug abuse is usually set as the 
standard for addiction studies48 due to comparative studies showing that drug 
addiction was more common among men than among women. In most cases, this is 
due to the ideology that males generally start using drugs at an earlier age and are 










1.4  Drug identification and quantification 
 
The importance of having a reliable technique to identify a drug, or drugs, within a 
sample is crucial since they provide valuable information on drug prevalence, 
undetectable movements, emergence of new drugs of abuse and to develop 
strategies to reduce the harms associated with substance misuse and abuse. Several 
methods currently employed to identify the drug present and subsequently quantify 
them include gas chromatography-mass spectrometry (GC-MS), nuclear magnetic 
resonance (NMR) spectrometry and infrared (IR) spectroscopy. 
 
1.4.1 Gas Chromatography - Mass Spectrometry (GC-MS) 
 
GC-MS is an analytical method which is currently the ‘gold standard’49 in the analysis 
of chemical compounds, this is due to this method being a simple and sensitive 
identification system for the detection of a broad spectrum of drugs. Several methods 
have been developed using this detection method already in the field of drug 
detection and analysis. For example, in 2000, a rapid detection method was 
developed for the identification of sympathomimetic amines in urine.50 These are 
drugs, such as amphetamine, ephedrine and 3, 4-
methylenedioxymethamphetamine, which effect certain characteristics of the 
sympathetic nervous system by stimulation the sympathetic nerves and produce 
physiological effects. Reports have been made of GC-MS being used for metabolic 
profiling; this simply refers to the detailed analysis of samples.51  
The GC-MS detection method can be used to perform both targeted and non-
targeted analyses,51 where targeted analysis is when the analytes have been defined 
in advance, so they are known and are simply being detected. Non-targeted analysis 
allows detection of both known and unknown chemicals. Gas chromatography works 
on the principle that a mixture will separate into individual substances when heated. 
GC analysis was performed using an Agilent 7890B GC System (Agilent Technologies, 
Wokingham, UK) and data was acquired using the Agilent Mass Hunter Software 
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(Agilent Technologies, Wokingham, UK). The separation of molecules in a sample 
requires the use of a stationary phase, in this case a HP-5 capillary column (BGB 
Analytik, Switzerland) as it is non-polar and useful for the separation of semi-volatiles, 
drugs, alkaloids etc. Once the sample has been eluted from the column a temperature 
gradient is usually employed to an unknown sample in order to optimise the 
temperature programming. The quantification of the MDMA was obtained in SIM 
(single ion monitoring) mode in order to narrow down the window in which the 
molecular ions of the molecule is analysed. Ions were selected as a result of the 
fragment in the analysis, when MDMA was ionised by a beam of electrons, the 
molecule was broken into smaller fragment. This fragmentation process is specific to 
all molecules so allows identification and identification of unknown.  In this 
investigation GC-MS was used as a comparative method used to validate the 




1.4.2 Infrared (IR) Spectroscopy  
 
IR spectroscopy deals with the infrared region of the electromagnetic spectrum, 
which is a frequency of light with a longer wavelength and lower frequency than 
visible light. It works on the principle of vibrational spectroscopy which assesses the 
stretching or bending vibrations of molecules when they absorb photons of specific 
energy.52 IR spectroscopy can be used as the solution to various issues revolving 
around drug identification. This includes its use in testing the purity of drug samples 
and observing interactions between the drug and various excipients, which act as a 
vehicle to deliver the drug into the system. 
A method for the rapid verification of drugs was developed in 1991, focusing on the 
basis on IR spectroscopy.53 Spectra for the samples were collected and the Agilent 
Mass Hunter software was used to identify the formula using a pre-installed library 
containing the chemical database, which is useful for obtaining reliable results with 
minimal operational use. Identification of additives were also achievable by 
subsequent data retrieval and searching against spectral libraries. This technique has 
also been reportedly used to identify counterfeit drugs in 2001,54 where the spectrum 
of a sample was compared to a typical spectrum of the authentic drug, similar to the 
previous study. The samples used in this were said to contain the products Aspirina 
and Melhoral (both containing aspirin and used for pain relief). Statistical analysis of 
the samples allowed identification of the counterfeit samples from the genuine 
drugs, displaying the results clearly on a Coomans graph, which compares the 
distance of the results obtained from the sample to that of the model data for both 
drugs. 
 
1.4.3 Nuclear Magnetic Resonance (NMR) 
 
Nuclear Magnetic Resonance (NMR) is one of the most powerful and widely used 
analytical techniques in chemical research. It is a robust method, which can rapidly 
analyse mixtures at the molecular level without requiring a multitude of separation 
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and/or purification steps. In drug analysis, the usefulness of 1H and 13C nuclear 
magnetic resonance spectroscopy (1H and 13C NMR) arises due to the fact that 1D and 
2D data sets can be acquired, from which the atom connectivity can be established. 
This facilitates a route to establish the molecular structure of a compound. 55 A recent 
example of NMR being studied in drug identification was in 2011, where it was used 
to identify counterfeit drugs and detect drugs that were at a lower concentration 
than the active pharmaceutical ingredient (API),56 in addition to other contaminants 
present. The application of 1H NMR spectroscopy allowed for tablets of counterfeit 
drugs said to contain heparin (a blood thinner) and Viagra (used to treat erectile 
dysfunction) to be compared to spectra of genuine drugs. Resultantly, the 
compositions and chemical components of the counterfeits were determined.57 
Alternatively, NMR is not only used in drug identification and quantification. For 
example, it can be used in drug discovery where its application can also be used in 
identifying how a substance interacts with biological macromolecules within an 
organism.58 The goal of using NMR for this process is to justify the ligands have 
desirable interactions, so they can be subsequently developed into drugs. Due to the 
high sensitivity of the analytical method, even the weaker interactions can be 
detected, allowing for the screening of the smallest compounds and fragments.  
Other uses for 1H and 13C NMR spectroscopy in drug analysis include: 
- Identifying compounds present in unknown drug samples using a pre-installed 
library containing the chemical database as was done in 2018 where samples 
in drug-related case was qualitatively analysed using a desktop NMR 
spectrometer.59 
- Quantifying the level of impurities as described in a 2014 study where a 
quantitative NMR (q-NMR) was developed and used an assessment measure 
for testing the purity of assays.60 
- Quantifying the content of residual solvents as shows was possible in a study 




- Identifying the isomeric composition of chemical components as in 1996 
where the isomers of a nonsteroidal anti-inflammatory drug was separated in 
human urine.62 
- Producing an assay of single drugs or drug compositions as shown in a 2019 
study where q-NMR was used to assay different MDMA tablets seized from 






The aims of this project are as follows: 
 
- Investigate the application of bench-top nuclear magnetic resonance (NMR) 
spectroscopy for the rapid, sensitive and field deployable detection of controlled 
drugs (MDMA) and potentially extend this to new psychoactive substances (NPS). 
 
- Build up the co-developed, patented technology between Manchester 
Metropolitan University (MMU) and Oxford Instruments and focus on the application 
of the technology to determine the presence (qualitative) and levels (quantitative) of 
MDMA present in seized samples (tablets) provided by law enforcement agencies. 
 
- Development and validation of the method using International Conference on 
Harmonisation (ICH) and United Nations Office on Drugs and Crime (UNODC) 
guidelines and cross-validation of the method using an approved ‘gold standard’ 
method (in our case GC-MS). 
 
- Provide data on the content of MDMA within seized samples, which can be 
used to further refine the field-deployed technology and inform law enforcement, 
healthcare professionals and front-line responders of potential and emerging 










All reagents were of commercial quality (Sigma-Aldrich, Gillingham, UK) and used 
without further purification. Solvents (Fisher Scientific, Loughborough, UK) were 
dried, where necessary, using standard procedures.64 High field 1H, 13C, 1H-1H COSY, 
HMBC and HMQC NMR (50 mg/mL of MDMA in d6-DMSO) spectra were acquired on 
a JEOL AS-400 (JEOL, Tokyo, Japan) NMR spectrometer operating at a 1H resonance 
frequency of 400 MHz and referenced to the residual solvent peak (δ = 2.50, d6-
DMSO). Low field 1H NMR spectra were acquired on an Oxford Instruments bench-
top Pulsar® NMR spectrometer operating at a 1H resonance frequency of 60 MHz and 
referenced to the residual solvent peak (δ = 2.50, d6-DMSO). Infrared spectra were 
obtained in the range 4000 – 400 cm-1 using a Thermo Scientific Nicolet iS10ATR-FTIR 
instrument (Thermo Scientific, Rochester, USA).  GC-MS analysis was performed using 
an Agilent 6850 GC and a MS5973 mass selective detector (Agilent Technologies, 
Wokingham, UK). The mass spectrometer was operated in the electron ionisation 
mode at 70 eV. Separation was achieved with a capillary column (HP5 MS, 30 m Å∼ 
0.25 mm i.d. 0.25 μm) with helium as the carrier gas at a constant flow rate of 1.0 
mL/min. The oven temperature programme started at 50 °C, increased at 30 °C/min 
and was held at 290 °C for 2 minutes. A 1 μL aliquot of the samples (qualitative 
analysis, calibration standards and test solutions) were injected (manually) with a 
split ratio of 20:1. The injector and the GC interface temperatures were both 
maintained at 280 °C and 290 °C respectively. The MS source and quadrupole 
temperatures were set at 230 °C and 150 °C, respectively. Mass spectra were 
obtained in full scan mode (50 – 550 amu).  
 
3.1 MDMA Synthesis 
 
Racemic MDMA.HCl was prepared in house via the sodium borohydride method65 




3,4-methylenedioxymethamphetamine: 1H NMR (d6-DMSO, 400 MHz, 298 K), δ 
(ppm) = 9.25 (s, 2H, N-H2), 6.87 (d, 4JHH = 1.43 Hz, 1H, Ar-H), 6.85 (d, 3JHH = 7.90 Hz, 
1H, Ar-H), 6.70 (dd, 4JHH = 1.43 Hz and 3JHH = 7.90 Hz, 1H, Ar-H), 5.99 (s, 2H, O2C-H2), 
3.25 (m, 1H, C-H), 3.11 (dd, JHH = 13.15 Hz and JHH = 4.28 Hz, 1H, C-H2), 2.58 (dd, JHH = 
13.15 Hz and JHH = 9.96 Hz, 1H, C-H2), 2.52 (s, 3H, C-H3), 1.09 (d, 3JHH = 6.52 Hz, 3H, C-
H3); 13C NMR (d6-DMSO, 400 MHz, 298 K), δ (ppm) = 101.4 (1C, O2CH2), 147.9 (1C, 
ArCO), 146.5 (1C, ArCO), 110.0 (1C, ArCH), 130.9 (1C, ArCCH2), 122.9 (1C, ArCH), 108.8 
(1C, ArCH), 38.4 (1C, ArCCH2), 55.8 (1C, CH2CHNHCH3), 30.1 (1C, NHCH3), 15.4 (1C, 
CHNHCH3); IR (ATR-FTIR), (cm-1): 2946 (N-H), 1489 (ArC=C), 1033 (Ar-O-CH3), 798 (C-
H). 
 
3.2 PMA Synthesis 
 
Racemic PMA.HCl was prepared in house, using a reported adaptation of the 
synthesis reported by Liu et al.66 and produced an off-white crystalline powder. A 
solution of anisaldehyde (27.2 g, 199.78 mmol) and nitroethane (18.0 g, 239.78 
mmol) in benzene (300 mL) was treated with cyclohexylamine (2.0 mL, 17.43 mmol) 
and refluxed until H2O ceased to accumulate. After the solvent was removed, the oily 
residue was cooled and crystallized producing 1-(4-methoxyphenyl)-2-nitropropene 
as yellow crystals, which were used without further purification. A suspension of 
lithium aluminium hydride (32 g, 843.21 mmol) in anhydrous Et2O (1 L) was stirred 
and crude 1-(4-methoxyphenyl)-2-nitropropene (32.6 g, 168.74 mmol) in Et2O was 
added at a steady rate. Reflux was then continued for 48 hours. The reaction mixture 
was cooled, and dilute H2SO4 was added. A solution of potassium sodium l(+)-tartrate 
tetrahydrate (700g, 2481.39 mmol) in H2O (600 mL) was added, along with 25% NaOH 
which was added until the pH was brought to >9. This aqueous phase was extracted 
with CH2Cl2 (3 x 200 mL). The oil produced was dissolved in isopropyl alcohol (100 
mL), neutralized with concentrated HCl, and then diluted with anhydrous Et2O (300 
mL) to provide white crystals of 4-methoxyamphetamine hydrochloride (PMA). Yield 
= 271.4 mg (14%) 1H NMR (d6-DMSO, 400 MHz, 298 K), δ (ppm) = 8.17 (s, 2H, N-H2), 
7.11 (dd, 3JHH 8.42 Hz, 2H, Ar-H), 6.85 (dd, 3JHH 8.42 Hz, 2H, Ar-H), 3.68 (d, 3H, OC-H3), 
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3.26 (s, 1H, C-H), 2.94 (dd, 2JHH = 13.38 Hz and 3JHH = 4.95 Hz, 1H, C-H), 2.55 (dd, 2JHH 
= 13.38 Hz and  3JHH = 9.20 Hz, 1H, C-H), 1.05 (d, 3JHH = 8.00 Hz, 3H, C-H3); 13C NMR 
(d6-DMSO, 400 MHz, 298 K), δ (ppm) = 55.6 (1C, OCH3), 114.5 (2C, ArCH), 158.6 (1C, 
ArCO), 130.8 (2C, ArCH), 129.2 (1C, ArCCH2), 39.7 (1C, ArCCH2), 48.7 (1C, CH2CHNH2), 
17.9 (1C, CHNH2CH3); IR (ATR-FTIR), (cm-1): 2914 (N-H), 1508 (ArC=C), 1032 (Ar-O-
CH3), 807 (C-H); MP = 208-209 °C. 
 
3.3 MDMA NMR Calibration 
 
MDMA (5 – 300 mg/mL) in d6-DMSO calibration standards were produced by 
dissolving the weighed amounts of MDMA in d6-DMSO (1 mL). The 1H NMR spectrum 
of the MDMA sample was acquired using a Pulsar® benchtop NMR spectrometer 
(Oxford Instruments, Abingdon, UK). A concentration vs. integral graph was plotted 
for each of the 3 H environments decided to be the focus of in this investigation: Ar, 
CH2 and Me. The chemical shift regions for each environment is [6.918 ppm to 6.444 
ppm], [6.036 ppm to 5.768 ppm] and [1.191 ppm to 0.669 ppm] respectively. 
 
3.4 MDMA GC-MS Calibration 
 
Stock solutions of MDMA.HCl (100 μg/mL) in MeOH (stock solution A), and eicosane 
(100 μg/mL) in MeOH (stock solution B) were prepared respectively. Five GC-MS 
calibration standards were produced all containing the same amount of the eicosane 
(10 μg/mL) and varying amounts of the MDMA.HCl solution: 5, 10, 15, 20 and 25 
μg/mL. The samples were run in SIM mode, using selected ions (m/z = 58.10, 77.00 





3.5 NMR Simulated Samples 
 
Simulated mixtures, of MDMA and calcium carbonate (CaCO3), were made up using 
CaCO3 (0.7790 g) and MDMA (2.0083 g) weighed using an AB104-S analytical balance 
(Mettler Toledo, Leicester, UK). The powders were homogenised using a pestle and 
mortar and 6 samples of approximately 0.46 g were extracted to determine the 
MDMA concentration by dissolving in d6-DMSO, filtering through a 0.45 um PDVF 
(polyvinylidene difluoride) syringe filter (Whatman, Sigma-Aldrich, Dorset, UK) 
directly into an NMR tube. The sample was then analysed. The concentrations were 
determined by comparing the integrals to the concentration vs. integral graph 
produced for each integral region: Ar, CH2 and Me. 
 
3.6 Unknown Samples Analysis By NMR 
 
Each of the 25 seized tablet samples of unknown and purported to be MDMA 
(ecstasy) identity were obtained from Greater Manchester Police via the MANchester 
DRug Analysis & Knowledge Ex-change (MANDRAKE) partnership and were stored 
and analysed in accordance with the UK Misuse of Drugs Act (1971) and Misuse of 
Drugs Regulations (2001). The samples were collected over the period August 2018 – 
August 2019. 
All of these samples were supplied in their solid, bulk, forms and were photographed 
(example shown in Figure 6). They were accurately weighed using an AB104-S 
analytical balance (Mettler Toledo, Leicester, UK), thoroughly homogenised using a 
pestle and mortar and added into a glass vial. 30 mg of the sample was removed to 
be used for GC-MS measurements. d6-DMSO (1 mL) was pipetted into the vial using 
an eVol® XR digitally controlled positive displacement dispensing system (Trajan, 
Victoria, Australia) with a 1 mL eVol® syringe and then filtered through a 0.45 μm 
PVDF (polyvinylidene difluoride) syringe filter (Whatman, Sigma-Aldrich, Dorset, UK) 





Figure 6 Representative photograph of seized pink bear MDMA tablets 
 
The 1H NMR spectrum of the MDMA samples was acquired in four scans and a 
relaxation delay of 60 s was utilised. The temperature of the probe was calculated to 
be 308.5 K by measuring the separation (in Hz, ∆δ) between the CH2 and OH signals 
of neat ethylene glycol and implementing the equation T [K] = 466.5 - 102.00 ∆δ.67 
After the NMR sample tube had been inserted, an automated procedure began 
whereby the instrument would lock on to the deuterated signature of DMSO (thus 
used as a chemical shift reference) before acquiring the 1H NMR spectrum. The 
collection of sample NMR data and the subsequent analysis took approximately 5 
minutes.  
Following acquisition, the data was processed in MNova (Mestrelab Research, 
Santiago de Compostela, Spain) using an automated script file. The processed free 
induction decay (FID) file was then analysed using a pattern recognition algorithm,67 
developed in-house using Matlab (The Mathworks Inc, Cambridge, UK). The spectrum 
was processed using a 1 Hz exponential in the T1 direction and phased accordingly. 
Integrals of the aromatic, methylene and N-CH3 groups were then obtained which 
had been referenced against a standard containing 100 mg of MDMA in 1 mL 
deuterated DMSO. Using the calibration plots as outlined in section 4.5, the amount 
of MDMA was determined. Each experiment sample was collected five times. The 
average integral is reported for each of the three resonances considered, with a 




3.7 Unknown Samples GC-MS 
 
Tablet samples were crushed into a powder using a pestle and mortar, and two 
masses of each sample were taken at 10% of the powder weight. The sample was 
dissolved in 100 mL MeOH and filtered using a fluted filter paper in to a beaker. 10 
mL of the tablet sample was extracted in to a 100 mL volumetric flask and 10 mL of 
eicosane solution (0.5 mg/mL of eicosane in MeOH) was added. The sample was then 
made up to 100 mL with MeOH to give a dilution factor of 1:10 and 0.5 μL of this 
solution was analysed on the GC with two injections following the calibration series 
which was injected three times. The three ions monitored were at m/z = 58.10, 77.00 
and 135.10 (for MDMA) and 43.00, 57.00 and 71.00 (for eicosane). Using the 
Qualitative Analysis Agilent Mass Hunter Software, the retention times for MDMA 
and eicosane appeared to be at 5.634 and 7.234 minutes respectively. A generalised 
GC method was used, and the chromatogram was obtained using a concentration 
gradient initiating at 50 °C and increasing at a steady rate of 30 °C / min until the 




4 Results and Discussion 
 
4.1 MDMA Synthesis 
 
MDMA synthesis was carried out using the sodium borohydride method.65 The 
synthesis began using the plant oil safrole (1-allyl-3,4-methylenedioxybenzene) and 
was oxidised into a ketone, PMK (3,4-methylenedioxyphenyl-2-propanone). From 
this compound, three routes can be utilised by which the MDMA base can be 
synthesised. In this instance, MDMA was synthesised by reductive amination, as 
shown in Scheme 1Error! Reference source not found. using route A.65 The MDMA 
base was then converted to the HCl salt. 
  








MDMA was then fully characterised using NMR, GC-MS and IR. The 50 mg/mL d6-
DMSO sample was used to carry out the analysis and the structural configuration 
was determined.  
 
4.2 MDMA Characterisation  
 
4.2.1 NMR Characterisation 
 
The supplied sample of MDMA was analysed using 1H and 13C NMR spectroscopy to 
ascertain its analytical purity. A combination of 1D and 2D methods were employed 
for complete structural elucidation.  
MDMA has 9 1H NMR resonances, and therefore 9 unique 1H NMR environments 
(chemical structure shown in Figure 7 along with atom numbering system), 
accounting for 16 proton nuclei. This is reflected in the 1H NMR spectrum for the 
compound (Figure 8). The two ammonium protons at position 10 are observed at 
9.25 ppm as a broad singlet; this is due to them exchanging in the ammonium salt 
form. The aromatic protons located at position 6 appears as a doublet of doublets at 
around 6.70 ppm. This is due to the proton at positon 6 having a 4JHH coupling of 1.43 
Hz and a 3JHH coupling of 7.90 Hz to protons 4 and 7 respectively. Protons 4 and 7 
both appear as doublets centred at 6.87 and 6.85 ppm resepectively.  
 
 




The two protons located at position 1 are observed at 5.99 ppm as a singlet. The peak 
sits in a relatively low-field position due to the protons being deshielded by the 
oxygens bound to the carbon centre thus increasing the frequency. 
There is a chiral centre located at position 9 in the structure on MDMA containing a 
single proton. This is presented as a multiplet at approximately 3.25 ppm with a 3JHH 
coupling of 6.52 Hz from the methyl and 3JHH couplings of 13.15 Hz and 4.26 Hz at 
3.11 ppm, and couplings of 13.15 Hz and 9.96 Hz at 2.58 ppm from the methylene. 









Figure 9 1H-1H COSY NMR spectrum of MDMA collected in d6-DMSO 
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The methylene group with two protons at position 8 is separated into two individual 
doublets at 3.13 ppm and 2.59 ppm that have 3JHH couplings of 4.26 Hz and 9.92 Hz 
respectively. The methyl group attached to the ammonium centre containing three 
protons at position 11 are observed at 2.52 ppm as a singlet. This peak does not show 
any coupling. The three protons on the methyl group at position 12 are the most 
shielded in the spectrum and are present at 1.11 ppm as a doublet with a 3JHH coupling 
of 6.52 Hz. This is due to there being the greatest amount of shielding of the protons, 
so they sit at the highest-field position on the spectrum. 
The 13C{1H} NMR spectrum of MDMA (Figure 10) reveals that the structure contains 
11 unique carbon environments. In order to be able to identify which peaks are 
associated with the corresponding carbons, a DEPT-135 NMR spectrum of MDMA 
(Figure 11) was collected in order to simplify this. This is due to the quaternary 
carbons at positions 2, 3 and 5 on the structure (Figure 7) at 147.41 ppm, 146.04 ppm 
and 130.45 ppm are no longer observed. The carbon atoms containing one (tertiary) 
or three protons (primary) are positive (point up) and the carbon atoms containing 
only two protons (secondary) are negative (point down). 
The two carbons at positions 1 and 8 both contain two protons, so are therefore 
secondary carbons. The methylene at position 1 is more de-shielded than the one at 
position 8, therefore will have a higher chemical shift and is seen at 100.9 ppm. 
Carbon 8 must therefore appear at 37.9 ppm. The three carbons on the aromatic ring 
at positions 7, 6 and 4 on the structure all contain one proton and are tertiary. They 
appear at 122.4 ppm, 108.3 ppm and 109.5 ppm respectively. The two methyl groups 
at positions 11 and 12 contain 3 protons (primary) and will sit at the lowest chemical 
shifts. Due to the carbons at position 11 being more de-shielded, they will lie most 
up-field at the lowest frequency so therefore is assigned the peak at 141.9 ppm. This 
leaves the peak at 29.5 ppm being assigned to position 12. Finally, the chiral centre 









Figure 11 DEPT-135 13C{1H} NMR spectrum of MDMA collected in d6-DMSO 
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The 1H-13C HMQC NMR spectrum of MDMA (Figure 12) was used to determine the 
connectivity of the protons and carbons using the 1H NMR spectrum and 13C{1H} NMR 
spectrum. From the HMQC spectrum it is seen that the proton located on position 6 
(Figure 7) is connected to the carbon at position 6 at 55.4 ppm. On inspecting the 
spectrum further, it is seen the protons located at position 8 are connected to the 
carbon at position 8 at 37.9 ppm. In addition, using the spectrum it is clear to identify 
the three peaks at 147.4 ppm, 146.0 ppm and 130.5 ppm were most certainly 









Position number 1H NMR δ / ppm 13C NMR δ / ppm 
1 5.99 (2H) 101.4 
2 N/A 147.9 
3 N/A 146.5 
4 6.87 (4JHH = 1.44 Hz, 1H) 110.0 
5 N/A 130.9 
6 
6.70 (4JHH = 1.42 Hz and 
3JHH = 7.88 Hz, 1H) 
122.9 
7 6.85 (3JHH = 7.92 Hz, 1H) 108.8 
8i 
3.11 (JHH = 13.15 Hz and 
JHH = 4.28 Hz, 1H) 
38.4 
8ii 
2.58 (JHH = 13.15 Hz and 
JHH = 9.96 Hz, 1H) 
38.4 
9 3.25 (1H) 55.8 
10 9.25 (2H) N/A 
11 2.52 (3H) 30.1 
12 1.09 (3JHH = 6.52 Hz, 3H) 15.4 
 




4.2.2 Gas Chromatography Characterisation 
 
A typical chromatogram for MDMA is provided overleaf (Figure 13). It shows the 
retention time at which MDMA elutes is at 5.62 minutes and the retention time for 
eicosane is 7.24 minutes. The chromatogram shows no distortion of the peak shapes, 
only with very little tailing occurring at base of each peak. The peaks are fairly 
symmetrical, and the base line shows very little background noise, deeming the 
method developed and therefore the mass spectrum of MDMA (Figure 14) fit for 
reliable analysis of the unknown suspected drug samples. Calibration standards were 
integrated and the peak area ratios (PARs) between MDMA and eicosane were 
calculated. These were then used to construct calibration series, plotting PAR vs. 
increasing concentration, producing a linear response. 
The limit of detection (LoD) is the lowest concentration of a component that can be 
reliably detected with a given analytical method. The limit of quantification (LOQ) is 
lowest concentration at which a component can be reliably measured, once 
detected, by an analytical method.68 They can be calculated using the signal to noise 
ratios (SNR) of the peaks seen in the GC chromatogram. This is simply a comparison 
of the level of a desired signal to the level of background noise.69 The LoD and LoQ 
were calculated as they are more efficient than just using the calibration. They can 
inform if a method is sensitive enough and can be compared to similar investigations 
that have already been published. In this instance, they were calculated in order to 
















The mass spectrum of MDMA (Figure 14) shows the base peak of the molecule at 
58.1 m/z, which is the ion with the greatest relative abundance in the molecule. The 
peak at 134.9 m/z is the largest fragment shown on the spectrum; however, it is 
unable to be the molecular ion peak as MDMA has a molecular weight of 193.25 
g/mol. This must therefore be the tropylium ion, formed by the fragmentation of an 
aromatic containing group (Figure 15). The spectrum of MDMA collected on the GC 
was compared to that available on the Cayman Chemical database70 (3,4-MDMA 
(hydrochloride), CAS Number 64057-70-1) and had very close similarity. 
 
 
Figure 15 MDMA tropylium ion formation 
 
4.2.3 Infrared Characterisation 
 
Infrared spectroscopy measures the vibrations of the bonds between the atoms 
within a molecule and based on this it is possible to determine the functional groups. 
The structure of MDMA (Figure 7) shows the most prominent functional groups of 
the molecule to be the aromatic region, the N-H bond and the C-O bond. The infrared 
spectrum of MDMA (Figure 16) shows the presence of these functional groups at 
wavenumbers 2946 (N-H), 1488 (aromatic C=C) and at 1032 cm-1 (C-O). There are also 
strong, broad and sharp peaks at 2711 cm-1 and 797 cm-1 showing the presence of 





Figure 16 IR spectrum of MDMA 
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4.3 PMA Characterisation 
 
MDMA tablets can potentially be adulterated with PMA, so the compound was fully 
characterised using NMR, GC-MS and IR. The 20 mg/mL d6-DMSO sample was used 
to carry out the analysis and the structural configuration was determined. This was 
so it could be identified if found in combination with MDMA.  
 
 
                                                                                PMA 
Scheme 2 The synthesis of 4-methoxyamphetamine hydrochloride (PMA).  Reagents/conditions: (a) NH4OAc / 
NaBH3CN / MeOH / 24h; (b) HCl (4M solution in 1,4-dioxane) 
 
4.3.1 NMR Characterisation 
 
 
Figure 17 Chemical structure of PMA with atom labelling shown 
 
PMA (chemical structure and atom labelling scheme shown in Figure 17) has seven 
1H environments and the 1H NMR spectrum shown in Figure 18 reflects this. The 
protons at positions 2 and 7 occupy the same 1H environment as do the protons at 
positions 4 and 6. The aliphatic chain of PMA consists of four discrete 1H NMR 




ppm and integrate to three hydrogens. A 3JHH coupling of 8.00 Hz is observed to the 
chiral centre at position 8. This peak shows a COSY interaction (Figure 19) to a single 
peak at 3.28 ppm; this peak is the chiral centre located at position 9. The chiral centre 
(C9) shows coupling to both diastereotopic protons in C8 located at 2.95 and 2.55 
ppm. The two diastereotopic protons appear as a doublets of doublets. The signal at 
2.94 ppm has two couplings; a 2JHH of 13.38 Hz and a 3JHH of 4.95 Hz. The other peak 
at 2.55 ppm has couplings of 13.38 Hz (2JHH) and 9.20 Hz (3JHH). Due to these two 
protons being easily interchangeable by rotation, it is difficult to determine exactly 
which proton corresponds to each peak. The amine protons at position 10 appear as 









Figure 19 1H-1H COSY NMR spectrum of PMA collected in d6-DMSO 
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The aromatic part of the 1H NMR spectrum differs significantly to MDMA. This is 
because of the different substitution patterns of the two molecules; PMA is 1,4-
disubstitututed whereas MDMA is 1,3,4-trisubstituted. The four aromatic proton 
nuclei of PMA are in two discrete environments and are observed at 7.11 and 6.85 
ppm on the 1H NMR spectrum. They both appear as doublets that display second-
order effects. The 3JHH coupling for these two environments are 8.42 Hz. As the 
methoxy group located at position 3 on the aromatic ring (Figure 17) is an electron-
donating group and is significantly more electron-donating than the aliphatic chain, 
this has the effect of shielding the protons ortho to it (positions 2 and 7). They are 
therefore the most shielded, and hence why they appear at 6.85 ppm in the 1H NMR 
spectrum. The protons meta to the methoxy group (positions 4 and 6) are only 
shielded by the aliphatic chain and thus they are more downfield of the other set of 
aromatic protons – they are present in the 1H NMR spectrum at 7.11 ppm. The 
reciprocal coupling of these two environments is reflected in the 1H-1H COSY NMR 
spectrum (Figure 19) by the presence of cross-peaks linking the two environments.  
The methoxy protons at position 1 (Figure 17) are isolated in the molecule and show 
no coupling, as evidenced by the lack of cross-peaks in the 1H-1H COSY NMR and that 
these protons present as a singlet in the 1H NMR spectrum. They are located at 3.68 
ppm; the de-shielded nature of the peak is due to the electron-withdrawing effects 
of the oxygen. 
PMA possesses eight different 13C environments and the 13C{1H} NMR spectrum 
(Figure 20) reflects this. The aliphatic chain has three different 13C environments at 
positions 8, 9 and 11. The carbon to which the diastereotopic 1H nuclei is attached 
(position 8) is located at 39.7 ppm. This peak is the only CH2 present in PMA and the 
corresponding DEPT-135 (Figure 21) shows only a single negative peak, which is again 
observed at 39.7 ppm. Furthermore, the 1H-13C HMQC NMR spectrum (Figure 22) 
shows that this peak possesses cross-peaks to both diastereotopic 1H nuclei located 
at 2.94 and 2.55 ppm. In addition, the 1H-13C HMBC NMR spectrum (Figure 23) shows 
a cross-peak that links this environment to the aromatic protons ortho to the aliphatic 
chain located three-bonds away. The methyl carbon of the aliphatic chain at position 
11 is located at 17.9 ppm. It is the most shielded carbon environment present in PMA. 
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The 1H-13C HMQC NMR spectrum shows a cross peak that links this environment to 
its corresponding proton nuclei at 1.05 ppm. Lastly, the chiral centre is observed at 
48.7 ppm on the 13C NMR spectrum. This peak is de-shielded by the adjacent nitrogen 

















Figure 23 1H-13C HMBC NMR spectrum of PMA collected in d6-DMSO 
58 
 
There are four aromatic carbons in structure of PMA (Figure 17). Two of these are 
quaternary and they are located at 158.6 and 129.2 ppm. The former is adjacent to 
the methoxy group that de-shields the carbon environment whereas the latter is 
coupled to the CH2 of the aliphatic chain which shields the environment. Both peaks 
are absent in the DEPT-135 NMR spectrum. Additionally, the peak at 158.6 ppm 
shows a cross peak to the methoxy protons located three bonds away at 3.26 ppm in 
the 1H NMR spectrum, whereas this interaction is not observed for the other 
quaternary carbon. The peak at 129.2 ppm instead shows cross-peaks to both 
diastereotopic protons, which are located two bonds away. Two further peaks are 
observed at 130.8 and 114.5 ppm. They are both positive in the DEPT-135 NMR 
spectrum and so are assigned as CH environments. The carbon environments ortho 
to the methoxy group are the most shielded, and hence appear at 114.5 ppm. The 
other aromatic CH environment is not as shielded and appears at 130.8 ppm. 
The methoxy carbon is located at 58.6 ppm in the 13C{1H} NMR spectrum. This peak 
is significantly more deshielded than the chiral centre. This peak shows a cross-peak 





Position number 1H NMR δ / ppm 13C NMR δ / ppm 
1 3.68 (3H) 55.6 
2 6.85 (3JHH 8.42 Hz, 1H) 114.5 
3 N/A 158.6 
4 7.11 (3JHH 8.42 Hz, 1H) 130.8 
5 N/A 129.2 
6 7.11 (3JHH 8.42 Hz, 1H) 130.8 
7 6.85 (3JHH 8.42 Hz, 1H) 114.5 
8i 
2.94 (2JHH = 13.38 Hz and 
3JHH = 4.95 Hz, 1H) 
39.7 
8ii 
2.55 (2JHH = 13.38 Hz and 
3JHH = 9.20 Hz, 1H) 
39.7 
9 3.26 (1H) 48.7 
10 8.17 (2H) N/A 
11 1.05 (3JHH = 8.00 Hz, 3H) 17.9 
 




4.3.2 Gas Chromatography Characterisation 
 
The chemical structure of PMA is similar to that of MDMA, however they have 
significantly different sized base peaks and PMA is structurally smaller than MDMA. 
This would suggest both compounds would elute at different retention times, and 
looking at the chromatograms of each drug, it is seen that MDMA (Figure 13) and 
PMA (Figure 25) would elute at 5.62 and 4.96 minutes respectively. This suggests that 
if a sample was to appear consisting of both these structures, the GC could 
successfully elucidate that both components were present. 
The mass spectrum of PMA (Figure 26) shows the base peak of the molecule at 44.0 
m/z, which is the ion with the greatest relative abundance in the molecule. The peak 
at 122 m/z is the largest fragment shown on the spectrum; however, it is unable to 
be the molecular ion peak as PMA has a molecular weight of 165.23 g/mol. This must 
therefore be the tropylium ion (Figure 24). The spectrum of PMA collected on the GC 
was compared to that available on the Cayman Chemical database71 (4-
methoxyamphetamine (hydrochloride), CAS Number 3706-26-1) and had very close 
similarity.  
 















Figure 26 Mass spectrum of PMA
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4.3.3 Infrared Characterisation 
 
The chemical structure of PMA (Figure 17) shows the most prominent functional 
groups of the molecule to be the aromatic region, the N-H bond and the C-O bond. 
The infrared spectrum of PMA (Figure 27) shows the presence of these functional 
groups at 2913 (N-H), 1507 (aromatic C=C) and at 1031 cm-1 (O-CH3). There is also a 
strong, sharp peak at 807 cm-1 showing the presence of the C-H bonds due to C-H 
stretching.  
In comparison to the IR spectrum of MDMA, the spectrum of PMA looks visually 
similar. As PMA and MDMA possess the same functional groups, and thus have 
similar stretches in the IR spectrum, it would be virtually impossible to identify both 
drugs being present in a mixture just using infrared spectroscopy with any degree of 
certainty. Therefore, IR data should be used in combination with other analytical 
techniques, such as NMR and GC-MS, when analysing samples suspected of 






Figure 27 IR spectrum of PMA
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4.4 Qualitative NMR results 
 
Prior to quantifying the amount of PMA and MDMA present in a sample, the samples 
were qualitatively analysed. 25 samples were provided by GMP for this purpose. 
Qualitatively analysis was performed on a 60 MHz 1H NMR spectrometer using an 
automated process as outlined in section 3. The pattern recognition algorithm 
employs a minimum distance classifier. The multivariate distance between the 
sample spectrum and each of the reference spectra is calculated. The sample is 
identified as the nearest reference compound, provided the ‘match score’ (equal to 
one minus the distance of the peaks to the reference spectra), exceeds an empirically 
determined threshold; if it does not, then the outcome is tentative, unreliable or 
unknown. The samples analysed were all identified as MDMA with hit scores of 
greater than 92.3%. 
The suspected drug samples were labelled with reference to their appearance. For 
example, the seized pink bear drug samples shown in Figure 6 were labelled ‘PB’ and 
numbered accordingly. So, the 1H NMR spectrum labelled PB02-04 would show the 
fourth 1H NMR scan for the second pink bear tablet. A large quantity of the tablet’s 
supplied were almost equivalent in size, weight and appearance: for example, the 
pink bear tablets all contained MDMA when qualitatively analysed using 1H NMR 
spectroscopy. Therefore, it was assumed these drugs were manufactured 
simultaneously and came from the same batch. The 1H NMR spectra for all the PB 
tablet samples were stacked (Figure 28) and showed they were indeed identical in 
appearance. They also contained the identifiable MDMA peaks present in the 1H NMR 
spectra: benzene, CH2 and methyl, confirming the samples contained MDMA. This 
would suggest that the batch-to-batch variability of this batch of MDMA tablets to be 
fairly low and had good uniformity. However, qualitative analysis using the NMR 
calibration graphs and the integrated NMR spectra for these samples showed all 
tablets had slightly different concentrations of MDMA per tablet, varying from 190.2 
to 228.5 mg MDMA per tablet. This therefore proved the batch to batch variability of 
the tablets to be higher than first suspected. 
66 
 
The remaining tablet samples were grouped separately as they shared no similarities 
in appearance. The 1H NMR spectra for the samples were stacked (Figure 29) and 
showed similarities in appearance. They all contained the MDMA peaks present in 
the 1H NMR spectra, confirming the samples contained MDMA. Using the NMR 
calibration graphs and the integrated NMR spectra for these samples, qualitative 
analysis of this batch gave results within the range stated by the EMCDDA and gave 
reasonable figures to be compared to the gold standard GC method. 
As the qualitative analysis of the seized samples revealed that only MDMA was 
present, quantification methods were developed solely for MDMA. NMR and GC-MS 
were selected as the techniques to be used to quantify MDMA. Firstly, an NMR 
method was developed, that began with a consideration of the T1 values of specific 









Figure 29 1H NMR spectra of a range of tablets which were confirmed to contain MDMA 
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4.5 Quantification of MDMA by NMR  
 
4.5.1 T1 data for MDMA 
 
The T1 relaxation time, also known as the spin-lattice (or longitudinal) relaxation time, 
is used in NMR to quantify the rate of transfer of energy from the nuclear spin system 
to its neighbouring molecules,72 i.e. it is a measure of how quickly the nuclear spin 
recovers to its ground state in the direction of the z-axis. The return of excited nuclei 
from the high energy state to the low energy or ground state is associated with loss 
of energy to the surrounding nuclei. The T1 relaxation rate is the reciprocal of the 
time (1/T1)73 and is simply another way to express the relaxation time. T1 relaxation 
is fastest when the rotation of the nucleus, from its ground state to an excited state, 
matches that of the Larmor frequency. The Larmor frequency refers to the rate of 
change in the orientation of the rotational axis of the magnetic moment of the proton 
around the external magnetic field.74 As a result, T1 relaxation is dependent on the 
main magnetic field strength. Molecules with stronger bonds will have a higher 
magnetic field strength and will ultimately be associated with longer T1 times. As the 
concentration of the sample increases, the T1 is expected to decrease. As the 
concentration of the sample increases, the T1 is expected to decrease. The shorter 
the T1, the quicker the return of excited nuclei from the high energy state to its 
ground state. 
T1 plots were produced for 5, 50, 75, 100, 125, 150, 200, 250 and 300 mg/mL MDMA 
in d6-DMSO samples and the aromatic (Ar), CH2 and Me environments were 
integrated. The results were tabulated (Table 3) and a calibration graph was 
produced (Figure 30). The graph supports the definition of how the T1 is expecting to 
change as concentration changes as it clearly demonstrates a negative gradient 
showing that the T1 decreases for each concentration at each environment as the 


















Table 3 Change in T1 with varying concentrations of MDMA (mg/mL) 
 
 
 T1 (s) 
MDMA conc. (mg/mL) Aromatics CH2 CH3 
5 1.79 1.24 0.55 
50 1.45 1.03 0.48 
75 1.36 0.91 0.46 
100 1.3 0.83 0.43 
125 1.14 0.73 0.4 
150 1.08 0.69 0.38 
200 0.93 0.62 0.36 
250 0.82 0.52 0.32 




Figure 30 Change in T1 with varying concentrations of MDMA (mg/mL)
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4.5.2 NMR Calibration 
 
A calibration curve was produced using known concentrations of MDMA in order to 
determine the concentration of MDMA present if found in suspected drug samples. 
The precision and accuracy of the concentration calculated for the unknowns using 
the graph are dependent on the calibration curve, specifically the R2 value, which 
describes the linearity of the graph and how close the data points are to the fitted 
line of regression. 
The MDMA in d6-DMSO standards were analysed using 1H NMR and the results 
tabulated (Table 4). These data were used to produce 3 calibration curves using the 
three most prominent peaks visible in the 1H NMR spectrum: the phenyl ring (Figure 
31), the dioxymethylene CH2 (Figure 32) and the methyl adjacent to the chiral centre 
(Figure 33). These environments were chosen as they were isolated, therefore more 
accessible and easier to pick out. The 1H spectrum of MDMA (Figure 8) proves this as 
the environments do not interact with each other or any other proton environments 
in the molecular structure. The amounts of MDMA chosen were 50 - 300 mg/mL 
MDMA in d6-DMSO as the EMCDDA shows people undertaking in drug festival 
analysis shows a range of concentrations for the substance so the dose of 300 mg/mL 
was chosen to encompass all potential doses that have perceived to be circulating. 
The graphs had good linearity with an R2 value of 0.9979, so therefore using the 
calibration graphs, the quality of the calibration standards was able to be assessed 
and the gradient of the graph would ultimately be used to determine the 
concentration of MDMA in a sample by comparing the unknown to a set of standard 















50 1 1 1 45.40 42.76 43.31 
100 1.83 1.84 1.89 99.30 99.91 102.25 
150 2.69 2.7 2.78 155.14 158.41 161.19 
200 3.44 3.4 3.3 203.85 206.03 195.62 
250 4.15 4.08 4.13 249.95 252.29 250.59 
300 4.84 4.67 4.84 294.75 292.42 297.61 
 















Figure 33 Calibration plot for the methyl 1H nuclei of MDMA over the range 50 -300 mg/mL. The abscissa provides the normalised integral for each concentration analysed 
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4.5.3 Errors associated with the NMR quantification method 
 
Errors were calculated for the results of the MDMA NMR calibration (Table 5) using 
the calibration graphs and, due to all the values being known, the precision of the 
calculations were able to be determined. The R2 value is statistical measure of how 
close the data are to the line of best fit, and the closer to 1 the value is, the better 
correlation there is between the two variables in question. In this case the plots 
showed good linearity, with R2 values of over 0.9950. Removal of each of the points 
allows to calculate errors associated with this plot, this was then tabulated and shows 
that the average error on each of the points was approximately 2.36%, which equates 
to 4.13 mg of MDMA. The result is given as a percentage relative standard deviation 
(%RSD), which is a measure of precision and of how repeatable the method is. This is 
calculated using the equation: 
%RSD =  (
SD
mean
) × 100 
where SD = the standard deviation and the mean = the mean of all the values.  
In order for the experiment to have good repeatability, the %RSD must be no greater 
that 2%, this means if somebody else was to repeat the experiment exactly, they 
should get exactly same result less than 2% within error range. The %RSD calculated 




Conc. all points included / mg/mL Conc. removed point 1 / mg/mL Conc. removed point 2/ mg/mL 
Ar CH2 Me Ar  CH2  Me  Ar  CH2  Me  
45.40 42.76 43.31 40.13 33.90 35.31 45.05 42.59 44.46 
99.30 99.91 102.25 95.46 93.47 96.68 98.94 99.73 103.01 
155.14 158.41 161.19 152.80 154.46 158.06 154.79 158.23 161.57 
203.85 206.03 195.62 202.80 204.11 193.93 203.49 205.85 195.78 
249.95 252.29 250.59 250.13 252.34 251.17 249.59 252.11 250.38 
294.75 292.42 297.61 296.13 294.18 300.13 294.40 292.25 297.09 
         
Conc. removed point 3/ mg/mL Conc. removed point 4/ mg/mL Conc. removed point 5/ mg/mL 
Ar  CH2  Me  Ar  CH2  Me  Ar  CH2 Me  
47.16 45.11 46.61 46.04 43.23 42.66 45.35 42.41 43.22 
101.05 101.87 105.17 100.29 100.37 101.21 99.24 99.55 102.16 
156.90 159.97 163.72 156.50 158.87 159.76 155.09 158.06 161.11 
205.60 207.27 197.93 205.52 206.49 193.98 203.79 205.68 195.54 
251.70 253.22 252.53 251.92 252.75 248.58 249.89 251.93 250.50 
296.51 293.08 299.25 297.02 292.89 295.29 294.70 292.07 297.52 
         
Conc. removed point 6/ mg/mL  % RSD   
Ar CH2  Me   Ar CH2  Me    
47.53 46.23 44.50  2.67 4.35 3.91   
100.06 100.77 102.67  1.96 2.97 2.83   
154.49 156.62 160.84  1.48 1.92 1.88   
201.96 202.07 194.83  1.46 1.87 1.48   
246.89 246.23 249.08  1.81 2.58 1.42   
290.56 284.54 295.49  2.35 3.49 1.95   
   AVERAGE 1.95 2.86 2.25 = 2.35  
Table 5 Errors in MDMA calibration plots 
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In this instance, it would appear the aromatic environment has lowest error, followed 
by Me and then CH2. However, although it would seem fitting to simply use this 
environment for the qualitative and quantitative analysis of MDMA, the use of this 
peak must be used with caution. This is because, as seen in Figure 34, the aromatic 
protons are not simply an environment, but an ensemble of environments. It is 
therefore difficult to resolve individual T1 values for the aromatic nuclei. This would 
suggest that the Me and CH2 environment are more robust as they are singular 
environments. However, the appearance in the 1H spectrum as a shoulder on the 
methyl peak due to stearate has been reported76 and thus integrating this peak could 
be challenging. This would point to the CH2 peak being the single best environment 
to use even though statistically it has the highest error. An additional reason to why 
this would be the best environment to use is the protons contained within the 
environment are not exchangeable protons. Therefore, the calculated integral should 
be accurate as they cannot be exchanged with solvent and should give a fairly 
accurate representation of how many protons are in the environment, thus enabling 
the concentration of MDMA in the sample to be determined. 
There are several sources of error within the spectra themselves when integrating 
the proton environments in order to calculate the concentration of MDMA present 
in the sample. For example, it was seen with the CH2 environment the signals were 
tailing and broadening as the MDMA concentration increased, meaning the ability to 
integrate became more challenging, therefore increasing the error associated with 
calculating the final concentration. Therefore, it should be noted the peaks cannot 





Figure 34 100 mg/mL MDMA standard 1H NMR spectrum 
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4.6 Quantification of MDMA by GC-MS  
 
4.6.1  GC-MS calibration 
 
Similar to the NMR MDMA calibration curve, a calibration curve was produced using 
known MDMA standards in order to determine the concentration of MDMA present 
if found in suspected drug samples. 
A calibration curve for MDMA (Figure 35) was obtained by performing GC analysis of 
samples of known concentrations, in this case 5 – 25 mg/mL of reference MDMA was 
used. Calibration standards were integrated and the peak area ratios (PARs) between 
MDMA and eicosane, which elute at retention times 5.634 and 7.234 minutes 
respectively. These were then used to construct calibration series, plotting PAR vs. 
increasing concentration. This produced a linear response (y = 0.0747x + 0.2341) with 
an R2 of 0.995, thus showing good linearity. Using the calibration plot, it was possible 
to assess the quality of the calibration standards and the gradient of the plot would 
ultimately be used to calculate the concentration of MDMA in a sample by comparing 
















MDMA 5 - 01 245.34 1230.24 0.1994  MDMA 5 0.1908 
MDMA 5 - 02 296.13 1463.36 0.2023  MDMA 10 0.4821 
MDMA 5 - 03 225.69 1289.09 0.1750  MDMA 15 0.8851 
MDMA 5 - 04 212.46 1157.58 0.1835  MDMA 20 1.2445 
MDMA 5 - 05 261.79 1284.81 0.2037  MDMA 25 1.7010 
MDMA 5 - 06 302.25 1669.33 0.1810    
MDMA 10 - 01 674.76 1525.71 0.4422    
MDMA 10 - 02 763.41 1612.31 0.4734    
MDMA 10 - 03 559.53 1101.66 0.5078    
MDMA 10 - 04 675.41 1357.3 0.4976    
MDMA 10 - 05 692.69 1354.85 0.5112    
MDMA 10 - 06 745.12 1619.35 0.4601    
MDMA 15 - 01 1242.93 1367.37 0.9089    
MDMA 15 - 02 1369.01 1617.71 0.8462    
MDMA 15 - 03 1295.42 1554.61 0.8332    
MDMA 15 - 04 1139.14 1170.99 0.9728    
MDMA 15 - 05 1077.1 1161.03 0.9277    
MDMA 15 - 06 944.28 1148.64 0.8220    
MDMA 20 - 01 2475.85 2392.18 1.0349    
MDMA 20 - 02 1785.25 1223.08 1.4596    
MDMA 20 - 03 1577.12 1402.59 1.1244    
MDMA 20 - 04 1689.57 1322.27 1.2777    
MDMA 20 - 05 2025.14 1659.92 1.2200    
MDMA 20 - 06 2128.62 1576.49 1.3502    
MDMA 25 - 01 3525.66 1975.85 1.7843    
MDMA 25 - 02 3413.98 2035.12 1.6775    
MDMA 25 - 03 3453.83 2038.65 1.6941    
MDMA 25 - 04 3787.81 2379.46 1.5918    
MDMA 25 - 05 3580.27 2006.76 1.7841    
MDMA 25 - 06 3082.34 1840.88 1.6743    
 
Table 6 GC calibration table for MDMA over the range 5 - 25 mg/mL showing calculated peak area and average 









4.6.2 GC-MS Errors 
 
Similar to the NMR calibration, the error was calculated for the GC calibration curve 
for MDMA. The graph produced had an R2 of 0.9950, showing good linearity. Removal 
of each of the points allowed the error associated with this plot to be calculated and 
was found to be 2.52%. The result is given as a percentage relative standard deviation 
(%RSD). The %RSD calculated for the calibration graphs is approximately 3%, and 
therefore higher than that calculated for the NMR calibration curve. This would 
suggest the NMR method is more reproducible and would produce a more 
meaningful result with higher confidence than that of the GC. 
Several sources of error associated with the method involve the integration method, 
as with the NMR method. With both the MDMA and eicosane peaks, the signals were 
tailing and broadening, and the baseline became noisier meaning the ability to 
integrate became more challenging. This would potentially, therefore, increase the 
error in calculating the peak area ratios for the spectrum, and ultimately is associated 
with calculating the final MDMA concentration.  
Based on the errors associated with the measurements, both analytical methods can 
be compared due to their similar errors. It can also be seen that the difference in 




4.7 MDMA Simulated Samples 
 
Once calibration series was complete, simulated samples made up of a known 
concentration of MDMA were analysed to test the validity of the NMR method. 
Calcium carbonate (CaCO3) was used as the filling agent as it is a common, insoluble 
filling agent generally utilised in the production of tablets. It therefore acts as an 
excipient that could potentially be part of an MDMA tablet. In this case, as an MDMA 
tablet is trying to be simulated so it can be analysed, it would be useful to use 
something insoluble that MDMA can hopefully be extracted from, without 
adulterating the product. 
A known concentration of approximately 130 mg of MDMA per sample was used, so 
it was known what exact value was being sought after. This concentration was chosen 
as is close to the average found by EMCDDA, which reports an average of 125mg of 
MDMA per tablet.75 Theoretically, each sample from the same batch should contain 
the same amount of MDMA per sample. The mean in this sample is 129.5 mg so there 
seems to be good uniformity and batch-to-batch variation is quite low. The error was 
calculated and was given as a percentage relative standard deviation (%RSD), in this 
case it was calculated to be 5.41% which equated to ± 7 mg of MDMA. So, the amount 
of MDMA in the sample is 129.5 mg ± 7 mg. As the amount of MDMA that is needed 
to produce a toxic response is 300 mg,75 the method produced herein would be able 
to deduce this amount within acceptable limits.
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4.8  Quantification of MDMA in seized sample 
 
The quantification of MDMA in the 25 seized tablet samples of unknown identity 
were only attempted once the simulated samples quantified on the NMR had been 
proven to provide a successful result having been used on the model data. There is 
now a confidence that instrumental method is giving results which are in the right 
area with an acceptable level of error, so therefore it proves it is permitted to move 
onto unknowns and it will be possible to accurately determine MDMA concentrations 
and calculate errors. 
 
4.8.1 NMR Results 
 
The 25 suspected MDMA samples were photographed, homogenised and given a 
unique identifying number. 30 mg of the powder was removed, and the GC data was 
determined. The remainder of the powder was used to determine the MDMA 
concentration via 1H NMR. 1H NMR data were acquired first and the amount of 
MDMA found in the tablet samples ranged between 107.61 – 232.72 mg of MDMA 
per tablet. The mean value for the 25 samples was found to be 193.49 mg. This mean 
value is significantly higher than what was found by the EMDCCA, which reported an 
average of 125 mg MDMA per tablet.75 The mean amount of MDMA found via NMR 
for the tablet samples is significantly higher than that reported by the EMCDDA. This 
would suggest the average content of MDMA in tablets has increased in recent years 
and the EMCDDA should potentially re-assess the average it reports.  
The reason the average amount of MDMA may have increased in recent years could 
be due to the manufacturing process having an improved, increased yield, and 
therefore the purity of MDMA in the tablet is increased.75 This may be due to the 
popularity of the use of the drug in its tablet form, as compared to the purer crystal 
MDMA which is simply a version of the drug without the addition of a filing agent, 
simply because it is easier to take. The prevalence of MDMA use may be an additional 
reason to why the average amount of the drug per tablet has increased. For example, 
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a recent report from a UK festival onsite drug checking service reported that the most 
common drug identified was MDMA, with a positive result of almost 60%.76 
 
4.8.2 GC Results  
 
The suspected drug samples were analysed both quantitatively and qualitatively 
using GC. Similar to the NMR quantitative method, the spectrum for the sample 
collected on the GC was compared to a reference spectrum available on the Cayman 
Chemical database,70 and with close similarity it was proven the samples contained 
MDMA. Qualitative analysis was performed on all the samples containing MDMA and 
concentrations obtained were used to be compared to the concentrations of MDMA 
calculated for the same samples using the NMR analytical method.  
 
4.8.3 Results Comparison 
 
The results for the concentrations of MDMA found in the tablets samples for both 
analytical techniques were compared and contrasted. The GC method is considered 
to be an accurate representation of the concentration as it has previously been 
proven to be the most reliable technique, so the NMR data was compared to it. 
However, the error calculations for NMR and GC techniques, as described in sections 
4.5.3 and 4.6.2 respectively, showed the NMR analytical technique had a lower error 
than that of the GC. This could be the explanation as to why the data values obtained 
when calculating the difference in MDMA concentrations obtained using both 
methods varied were inconsistently higher and lower, ranging from 2.20 to 45.91 mg 
difference between the two.  
As presented on Table 7 overleaf, it is seen the GC data does not have good 
correlation with the NMR data across all the tablet samples, with varying 
underestimations and overestimations being calculated by the NMR relative to the 
GC. A possible reason for the underestimation of the NMR could be that MDMA was 
absorbed onto stearate that was taken out during the filtration process as certain 
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pigments could have been able to absorb MDMA better, so it was trapped in the filter. 
Also, the extraction process of the MDMA from the d6-DMSO solvent was not 
optimised as an extraction efficiency was not conducted, it was simply assumed 
solubility of MDMA was good. However, it is possible that if there was too much 
MDMA in the sample, the d6-DMSO could become saturated not all the compound 
would go into solution. This would result in some of the MDMA being filtered away 






Tablet weight / 
mg 
Crushed tablet 
weight / mg 
Average amount of MDMA 
in tablet by GC / mg 
Average amount of MDMA 
in tablet by NMR / mg 
Difference in amount 
of MDMA / mg 
Hit score from qualitative 
NMR analysis 
PB02 380.3 353.5 214.227 198.537 15.689 0.958 
PB03 387.9 376.7 200.116 197.920 2.196 0.947 
PB04 383.2 376.4 220.108 216.102 4.006 0.955 
PB05 397.9 392.1 248.152 228.483 19.669 0.953 
PB06 376.9 372.2 230.070 212.103 17.966 0.945 
PB07 380.1 372.6 197.819 211.209 13.389 0.945 
PB08 361.4 355.0 186.310 190.219 3.908 0.955 
PB09 387.9 386.4 184.919 218.944 34.024 0.944 
PB10 379.6 371.0 181.765 215.524 33.759 0.946 
PB11 378.5 374.2 168.221 211.036 42.814 0.946 
PB12 388.5 378.0 174.852 214.563 39.710 0.944 
PB13 383.9 379.5 176.798 222.708 45.909 0.942 
PB14 370.2 361.8 183.421 205.439 22.017 0.945 
PB15 375.1 368.1 177.303 200.673 23.370 0.945 
PU01 450.4 439.0 118.735 107.610 11.124 0.953 
PR01 448.4 428.9 172.864 200.450 27.585 0.923 
PR02 443.4 424.7 171.707 181.369 9.661 0.934 
YR01 503.1 486.1 183.602 224.763 41.161 0.931 
BR01 484.4 473.2 122.933 141.800 18.866 0.945 
YS01 289.3 264.8 121.996 139.935 17.939 0.961 
WA01 390.1 369.5 141.403 178.850 37.447 0.948 
GS01 500.4 476.7 146.298 158.490 12.191 0.958 
RB01 603.8 585.4 166.264 196.668 30.403 0.931 
BT01 457.8 438.9 206.139 232.723 26.584 0.946 
GH01 252.5 239.7 126.733 131.189 4.455 0.962 
 
Table 7 Comparison of MDMA concentrations obtained by NMR and GC 
90 
 
A possible reason for the overestimation of the concentration via NMR, or 
underestimation via GC, may be due to the solubility of MDMA being different in 
different solvents. This was due to both methods requiring different solvents in order 
to operate and carry out the analysis. Although the same tablet samples were 
analysed using both analytical methods, and the same concentrations of MDMA 
should have been expected, with the solvent being MeOH for the GC analysis and d6-
DMSO for the NMR analysis there is a possibility MDMA has a better solubility in 
MeOH. This would mean the solvent can take up more of the drug than d6-DMSO, as 
it becomes saturated at a higher concentration. This may explain the variation in the 
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The results from the analysis of the tablet samples showed that they contained only 
MDMA, as they all had NMR hit scores of greater than 92.3% and had the same 
retention times when analysed using the GC, indicating no PMA was present. 
However, should such tablets come about, it would be possible to differentiate them 
and distinguish between both compounds due to their distinctly different peaks on 
their 1H NMR spectra and different retention times on their GC chromatograms. IR 
spectroscopy, however, is not recommended for determining if a sample consists of 
MDMA, PMA or a combination. A detection method for MDMA was developed on 
the GC-MS using the calibration standards prepared and the graph produced from 
the results obtained from the method showed good linearity, with an R2 value of 
0.995, over the range of interest in relation to the concentration of MDMA present 
in the sample. This was then validated with a group of tablet samples containing 
MDMA and the results gave confidence in the method as the values obtained for the 
concentration of MDMA in the tablets was in line with the literature (EMCDDA). 
Therefore, the GC method developed could be used as a comparative method when 
developing an NMR method. 
Focusing on three discrete proton environments, it was possible to successfully 
detect and quantify MDMA via NMR. In order to test the validity of the NMR method, 
simulated samples consisting of MDMA and CaCO3 were tested. The results had low 
error, with the concentration of MDMA being calculated to have an average 0.5 mg 
difference to the expected value. The tablet samples used in the GC method were 
then analysed, and the outcome from the analysis showed the results for the 
concentration of MDMA in the tablets had a lower error than calculated on the GC. 
This would lead one to assume the NMR method has a higher accuracy and thus 
produces more reliable results. With the collection of the sample’s NMR data and the 
subsequent analysis taking approximately only 5 minutes, the method was also 
proven to be rapid.  
92 
 
Once the validity of the method was tested, it was confirmed accurate enough to be 
used on real street samples. 25 samples were analysed. 1H NMR analysis revealed 
that the amount of MDMA found in the tablet samples ranged between 107.61 – 
232.72 mg of MDMA per tablet. The mean value for the 25 samples was found to be 
193.49 mg. Analysis by GC-MS returned the range of MDMA content in the 25 
samples to be 118.74 to 248.15 mg. The mean value for the 25 samples was found to 
be 176.91 mg. Both mean values are significantly higher than what was found by the 
EMDCCA, which reported an average of 125 mg MDMA per tablet.75 This would 
suggest the average content of MDMA in tablets has increased in recent years and 
the EMCDDA should potentially re-assess the average it reports. Comparison of the 
NMR and GC-MS values of determined MDMA content indicated a variance of 2.20 
to 45.91 mg. This variance can partly be accounted for in terms of the difference in 
accuracy between the two methods, in that the GC-MS calibration plot possessed a 




6 Future Work 
 
This significant piece of research shows it is possible to both identify and quantify 
suspected drug tablet samples and an example of MDMA was the focus of this in this 
project. It has been proven that, in this instance, the method and technique by NMR 
was significantly better than the usual ‘gold-standard’ method of (GC) mass 
spectrometry.   
This investigation could be extended to look at adulterated MDMA samples to see if 
it can accurately determine multi-component mixtures. None of the samples 
analysed in this investigation contained PMA but if it was an early preliminary 
investigation, preliminary results would indicate this approach could be used as there 
are discrete signals that could be investigated. For example, Figure 36 overleaf shows 
a simulated NMR spectrum showing what would be the outcome spectrum if a 
sample containing a mixture of MDMA and PMA was analysed. This can be used to 
validate samples as they do not contain the PMA peaks shown. 
If the quantities of MDMA and PMA were to be calculated using this NMR technique, 
the signals to be used for the NMR quantification would likely be the CH2 (methylene) 
and OCH3 (methoxy). The aromatic region would likely not be used as the region is 
not viable, this is because in PMA the overlapping peaks would be difficult to 
distinguish, as within the combined spectrum. This shows that even though these 
samples do not contain PMA, it could be possible to distinguish mixed samples. If the 
technique works, due to the convenience of it, it could be used on different 
new/emerging drugs. The drug data base would only needed to be updated for 
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